Major Depressive Disorder

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

From FDA-approved at-home TMS and accelerated protocols to conversational AI matching group therapy outcomes, here are 5 psychiatry updates from May every clinician should know.

Transcranial magnetic stimulation for major depressive disorder is shifting toward accelerated (5x5 and SWIFT protocol) and at-home models (ProlivRx).

In a Q&A, psychiatrist Scott Wilke, MD, explains how accelerated TMS protocols are reshaping depression care and may help tailor treatment to specific neural circuits.

Shoshani discusses RCT data showing AI reduces anxiety and improves well-being, with outcomes comparable to those of group therapy.

FDA expands lumateperone for relapse prevention in schizophrenia, White House boosts psychedelics research, and AI reshapes psychiatry care debates in April 2026.

Pickering discusses data linking social risk factors to hospitalization and costs in MDD and implications for screening and care models.

The FDA approved a lumateperone sNDA adding relapse prevention data in schizophrenia based on a 63% reduction in relapse risk versus placebo.

Alva outlines how general clinicians should address patient questions on psychedelic therapies, including risks, approvals, and referral pathways.

Alva discusses infrastructure gaps, training demands, and unmet psychiatric need amid accelerated policy momentum for psychedelic therapies.

Following an April 18 executive order, Gus Alva, MD, discusses psychedelic mechanisms, evidence, and clinical considerations for psychiatry.

Preventive cognitive therapy may reduce relapse in recurrent depression by strengthening positive affect and addressing anhedonia, van Tol explained.

Research suggests preventive cognitive therapy reduced relapse risk in recurrent depression by improving positive affect and anhedonia, van Tol explained in an interview.

Murrough discusses ADAA 2026 findings evaluating azetukalner in MDD with anhedonia; exploratory outcomes suggest potential benefit despite nonsignificant primary endpoints.

In this interview, Miller discusses patients using ChatGPT for mental health advice, risks in severe mental illness, and how clinicians respond.

King discusses real-world patient use of AI tools for mental health advice and implications for clinical conversations.

Wescott discusses ADAA 2026 findings linking sleeping less than usual to next-day depression in high-risk youth, with interpersonal reactivity emerging as a potential mechanism.

Sisti discusses ethics, safety, and guardrails as patients use ChatGPT for mental health support and clinicians navigate AI’s role in psychiatry.

Phase 2 data presented at ADAA 2026 suggest azetukalner may improve anhedonia in MDD, even though the trial did not meet its primary neuroimaging endpoint.

Yockey discusses why girls, older teens, and multiracial youth remain at greater risk for depression despite overall post-pandemic improvements.

FDA approvals, at-home neuromodulation, phase 3 psychedelic data, and rising AI therapy use impacted the psychiatry field in the first quarter of 2026.

Survey data show a nearly 40% drop in adolescent depressive episodes post-pandemic, though clinicians should remain vigilant for disparities and unmet care needs, Yockey says.

Interview with Xue on UK Biobank data linking first-onset depression after age 50 to cognitive deficits and increased dementia risk.